Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501002 · ClinicalTrials.gov registry record · NA
Pilot Study to Evaluate the CereVasc® EShunt® System in the Treatment of Communicating Hydrocephalus
A NA study, sponsored by CereVasc.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT05501002: Clinical Trial NA study, sponsored by CereVasc.
NCT05501002 is a NA study that was terminated before completion, run by CereVasc. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05501002, a NA study, was terminated before completion, sponsored by CereVasc.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study will be to evaluate a novel, minimally invasive method of treating hydrocephalus in adults. The eShunt® System includes a proprietary eShunt® Delivery System and the eShunt® Implant, a permanent implant that is deployed in a mildly invasive, neuro-interventional procedure. The eShunt® Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.
Primary Outcome
At 24 to 48 hours after eShunt Implant deployment (with EVD remaining clamped) an ICP measurement that indicates: * ICP below 20 cmH2O with no periods longer than 15 minutes above 20 cmH2O * No episodes of ICP above 25 cmH2O with associated symptoms
Interventions
- DEVICE eShunt® Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-09-15 |
| Est. Completion | 2023-09-15 |
| Phase | NA |
Why NCT05501002 stopped before completion
NCT05501002 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which eShunt® Implant is the first listed.
NCT05501002 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05501002 about?
NCT05501002 is a clinical study titled "Pilot Study to Evaluate the CereVasc® EShunt® System in the Treatment of Communicating Hydrocephalus". The purpose of this study will be to evaluate a novel, minimally invasive method of treating hydrocephalus in adults. The eShunt® System includes a proprietary eShunt® Delivery System and the eShunt® Implant, a permanent implant that is deployed in a mildly invasive, neuro-interventional procedure. ...
What is the current status of trial NCT05501002?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2022-09-15. Estimated completion is 2023-09-15.
What interventions are being tested in trial NCT05501002?
The interventions under investigation include: eShunt® Implant (DEVICE).
Who is sponsoring clinical trial NCT05501002?
This trial is sponsored by CereVasc, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05501002's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI